Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...
GlobalData on MSN23h
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoCResults from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...
Hosted on MSN16h
Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPCShe noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...
Hosted on MSN21h
Talazoparib-Enzalutamide Improves Survival in Metastatic CRPCAdding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
Coinbase issued guidance for the 2025 fiscal year’s first quarter. It sees subscription and services revenue from $685 ...
DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...
The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...
The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback